The estimated Net Worth of Kathleen P. Bloch is at least $1.47 Million dollars as of 13 December 2023. Ms. Bloch owns over 37,594 units of Cytosorbents Corp stock worth over $467,941 and over the last 11 years she sold CTSO stock worth over $0. In addition, she makes $999,847 as Chief Financial Officer at Cytosorbents Corp.
Kathleen has made over 29 trades of the Cytosorbents Corp stock since 2014, according to the Form 4 filled with the SEC. Most recently she bought 37,594 units of CTSO stock worth $50,000 on 13 December 2023.
The largest trade she's ever made was buying 110,000 units of Cytosorbents Corp stock on 20 May 2014 worth over $26,400. On average, Kathleen trades about 9,057 units every 78 days since 2014. As of 13 December 2023 she still owns at least 467,941 units of Cytosorbents Corp stock.
You can see the complete history of Ms. Bloch stock trades at the bottom of the page.
Kathleen P. Bloch CPA serves as Chief Financial Officer of the Company. Ms. Bloch has more than 20 years of executive financial experience in both public and private companies. She became Chief Financial Officer of the Company in May 2013. Previously, she served as Chief Financial Officer of Laureate Biopharmaceutical Services, Inc., a leader in biopharmaceutical contract development and manufacturing from November 2010 to May 2013. Prior to that, from September 2007 to November 2010, Ms. Bloch served as Chief Operating Officer and CFO of PC Group, Inc., a $70 million in revenue, Nasdaq-listed, publicly traded company with a diverse group of holdings, including several medical device subsidiaries. Ms. Bloch served as Chief Financial Officer of Silver Line Building Products Corporation, one of the world’s largest manufacturers of vinyl windows, from August 1999 to August 2007. She began her career at the accounting firm of Peat Marwick International. Ms. Bloch holds an MBA and a BS in accounting from LaSalle University, and is a Certified Public Accountant.
As the Chief Financial Officer of Cytosorbents Corp, the total compensation of Kathleen Bloch at Cytosorbents Corp is $999,847. There are 2 executives at Cytosorbents Corp getting paid more, with Phillip Chan having the highest compensation of $1,404,380.
Kathleen Bloch is 65, she's been the Chief Financial Officer of Cytosorbents Corp since 2013. There are 4 older and 7 younger executives at Cytosorbents Corp. The oldest executive at Cytosorbents Corp is Dr. Robert H. Bartlett, 82, who is the Co-Chairman of Cardiac Surgery Advisory Board & Consultant.
Kathleen's mailing address filed with the SEC is C/O CYTOSORBENTS CORPORATION, 305 COLLEGE ROAD EAST, PRINCETON, NJ, 08540.
Over the last 16 years, insiders at Cytosorbents Corp have traded over $1,216,453 worth of Cytosorbents Corp stock and bought 832,447 units worth $1,058,402 . The most active insiders traders include James T. Gunton, Al Kraus, and Phillip P. Chan. On average, Cytosorbents Corp executives and independent directors trade stock every 34 days with the average trade being worth of $41,883. The most recent stock trade was executed by Alan D. Sobel on 13 December 2023, trading 22,557 units of CTSO stock currently worth $30,001.
cytosorbents (nasdaq: ctso) cytosorbents corporation is a leader in critical care immunotherapy, specializing in blood purification. its flagship product, cytosorb® is approved in the european union with distribution in 40 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury and pancreatitis, as well as in cancer immunotherapy. these are conditions where the risk of death is extremely high, yet no effective treatments exist. cytosorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. cytosorbents' purification technologies are based on biocompatible, highly porous polymer beads
Cytosorbents Corp executives and other stock owners filed with the SEC include: